S&P 5004,697.24+8.56(+0.18%) Dow 3037,466.11+25.77(+0.07%) Nasdaq14,524.07+13.77(+0.09%) Russell 20001,951.14-6.58(-0.34%) Crude Oil73.95+1.76(+2.44%) Gold2,052.60+2.60(+0.13%) Silver23.39+0.20(+0.85%) EUR/USD1.0945-0.0005(-0.04%) 10-Yr Bond4.0420+0.0510(+1.28%) GBP/USD1.2720+0.0035(+0.27%) USD/JPY144.5340-0.0190(-0.01%) Bitcoin USD43,988.05+490.60(+1.13%) CMC Crypto 200885.540.00(0.00%) FTSE 1007,689.61-33.46(-0.43%) Nikkei 22533,377.42+89.13(+0.27%) First Batch of 300,000 Units to be Fully Delivered in OctoberAinos Has Expanded Distribution in Multiple Channels and Plans to Scale Up Capacity for Expected Strong DemandSAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos”, or the “Company”), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has commenced shipping its VELDONA® Pet cytoprotein supplements in Taiwan.Mr. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of…
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan – Yahoo Finance
